Evidence map›Paper›PMID 41140442›Full record

Trial reportBlood neoplasia2025

Analyses of transplantation outcomes for adult patients with mixed-phenotype acute leukemia.

Tomoyasu Jo, Tadakazu Kondo, Shohei Mizuno, Shinichi Kako, Noriko Doki, Naoyuki Uchida, Masatsugu Tanaka, Tetsuya Nishida, Takahiro Fukuda, Masashi Sawa and 10 more

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood neoplasia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Tomoyasu JoDepartment of Hematology, Graduate School of Medicine, Kyoto University Hospital, Kyoto, Japan.
Tadakazu KondoDepartment of Hematology, Graduate School of Medicine, Kyoto University Hospital, Kyoto, Japan.
Shohei MizunoDivision of Hematology, Department of Internal Medicine, Aichi Medical University, Nagakute, Japan.
Shinichi KakoDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Noriko DokiDivision of Hematology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Naoyuki UchidaDepartment of Hematology, Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital, Tokyo, Japan.
Masatsugu TanakaDepartment of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
Tetsuya NishidaDepartment of Hematology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Japan.
Takahiro FukudaDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Masashi SawaDepartment of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan.
Yoshinobu KandaDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Satoru TakadaLeukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan.
Yuta HasegawaDepartment of Hematology, Hokkaido University Hospital, Sapporo, Japan.
Yuta KatayamaDepartment of Hematology, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima, Japan.
Satoshi YoshiharaDepartment of Hematology, Hyogo Medical University Hospital, Nishinomiya, Japan.
Koji KawamuraDivision of Clinical Laboratory Medicine, Department of Multidisciplinary Internal Medicine, Tottori University, Yonago, Japan.
Marie OhbikiJapanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan.
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan.
Masamitsu YanadaDepartment of Hematology and Oncology, Nagoya City University East Medical Center, Nagoya, Japan.
Yasuyuki AraiDepartment of Hematology, Graduate School of Medicine, Kyoto University Hospital, Kyoto, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mixed-phenotype acute leukemia (MPAL) is associated with poor prognosis. Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) can achieve long-term survival, optimal transplantation strategies remain unclear. We analyzed a national registry of adult patients with MPAL who underwent allo-HSCT between 2008 and 2022 in Japan. Among 417 patients, median age at transplant was 44 years (interquartile range, 32-55); 61% were male, 20% were

Identifiers

PMID41140442
PMCPMC12549542

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.